CD8A and neoplasm: Additionally, Figure 3 also showed that B-9-3, in both standard and tumor-bearing mice, increased the level of CD4+ and CD8+ T cells in both the blood and the spleen which may explain the higher antitumor effect of this drug in immunocompetent mice compared to nude mice.